Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Portfolio Pulse from
Novartis will present comprehensive seven-year disability outcomes and safety data for Kesimpta® at the American Academy of Neurology Annual Meeting in San Diego. The presentations will cover long-term treatment results in relapsing multiple sclerosis patients, including continuous treatment safety profiles and efficacy across different disease stages.
March 25, 2025 | 6:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Detailed presentations on Kesimpta® demonstrate sustained safety and efficacy over seven years, potentially reinforcing the drug's market position in multiple sclerosis treatment.
Comprehensive long-term data presentation could boost investor confidence in Novartis's neuroscience portfolio, particularly the Kesimpta® product line. Positive clinical results may attract more prescriptions and market share.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 95